Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
23.4 ^USD	+0.82%		-2.58%	-15.65%

May. 23	Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating	MT
May. 02	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	MT

Alkermes plc Receives a Notice from Sarissa Capital

February 07, 2023 at 06:04 am EST

On February 7, 2023, Alkermes plc announced that it has received a notice from Sarissa Capital Offshore Master Fund LP, stating that it intended to nominate 3 director candidates for election to the Company?s board of directors at the Company?s 2023 annual general meeting of shareholders.

Latest news about Alkermes plc

Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating	May. 23	MT
UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	May. 02	MT
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	May. 01	MT
Transcript : Alkermes plc, Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	May. 01	MT
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	May. 01	MT
Alkermes plc Reiterates Earnings Guidance for the Year 2024	May. 01	CI
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	Apr. 09	MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	Apr. 09	MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	Apr. 09	CI
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	Mar. 19	MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37	Mar. 19	MT
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors	Mar. 07	CI
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	Mar. 06	MT
Alkermes Shares Down After Downgrade From UBS	Feb. 20	MT
UBS Downgrades Alkermes to Sell From Neutral, Price Target is $25	Feb. 20	MT
Piper Sandler Raises Price Target on Alkermes to $39 From $32.54, Maintains Overweight Rating	Feb. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15	MT
Alkermes Shares Rise After Q4 Results, Guidance	Feb. 15	MT
Transcript : Alkermes plc, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Alkermes Q4 Non-GAAP Earnings, Revenue Increase; 2024 Outlook Issued -- Shares Gain Pre-Bell	Feb. 15	MT
Earnings Flash (ALKS) ALKERMES Posts Q4 Revenue $377.5M, vs. Street Est of $362.4M	Feb. 15	MT
Alkermes plc announces an Equity Buyback for $400 million worth of its shares.	Feb. 15	CI

Chart Alkermes plc

Duration

Period

More charts

Company Profile

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Associated Professional Sleep Societies Meeting - Abstract Number : 1323

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alkermes plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.4 USD

Average target price

34.27 USD

Spread / Average Target

+46.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALKERMES PLC	-15.65%	3.96B
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research